U
2024
Medication management is a service provided typically by pharmacists that aims to improve outcomes by helping people to better understand their health conditions and the medications used to ...
Report Code : A10470 | Category : Life Sciences
U
2024
Over-the-counter (OTC) medicines are drugs that are sold without the need for a prescription by registered pharmacists. People commonly reach for OTC pain medications to treat even the ...
Report Code : A12307 | Category : Life Sciences
U
2024
Carbinoxamine is an antihistamine agent used to cure conjunctivitis, vasomotor rhinitis, and hay fever. In addition, it is administered in combination with other medications to treat common cold, ...
Report Code : A12465 | Category : Life Sciences
U
2024
Dermatology is a therapy area that deals with the diseases of nails, hair, skin, and common conditions such as psoriasis, acne, eczema, and acne vulgaris. Dermatology drugs are used in the treatment and management of diseases related to hair, skin, and genital membranes.
Report Code : A14437 | Category : Life Sciences
P
2023
The Mexico Myasthenia Gravis Treatment Market is expected to reach a value of $40.8 million by 2032 during the forecast period 2023-2032
Report Code : A102156 | Pages : 89 | Category : Life Sciences
P
2023
The Germany Myasthenia Gravis Treatment Market was valued at $89.7 million in the year FY2022. The market growth is anticipated to continue during the forecast period, FY2023-FY2032
Report Code : A102160 | Pages : 86 | Category : Life Sciences
P
2023
The Italy Myasthenia Gravis Treatment Market size is expected to reach $78 million by 2032 during the period from 2023-2032
Report Code : A102161 | Pages : 80 | Category : Life Sciences
P
2023
The Japan Myasthenia Gravis Treatment Market is expected to reach a value of $236.9 million by 2032 during the forecast period 2023-2032
Report Code : A102164 | Pages : 75 | Category : Life Sciences
P
2023
The China Myasthenia Gravis Treatment Market was valued at $99.6 million in the year FY2022. The market growth is anticipated to continue during the forecast period, FY2023-FY2032
Report Code : A102165 | Pages : 79 | Category : Life Sciences
P
2023
The Middle East And Africa Myasthenia Gravis Treatment Market is expected to register a CAGR of 6.7% during the forecast period 2023-2032
Report Code : A102168 | Pages : 79 | Category : Life Sciences
Register and Earn 500 Loyalty Points
An Email Verification Code has been sent to your email address!
Please check your inbox and, if you don't find it there, also look in your junk folder.